Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study
Incidence of early-onset (
Gespeichert in:
| Veröffentlicht in: | CANCERS 2023, Vol.15 (3), p.688 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 688 |
| container_title | CANCERS |
| container_volume | 15 |
| creator | Lundqvist, Erik Myrberg, Ida Hed Boman, Sol Erika Saraste, Deborah Weibull, Caroline E Landerholm, Kalle Haapaniemi, Staffan Martling, Anna Myrelid, Pär Nordenvall, Caroline |
| description | Incidence of early-onset ( |
| doi_str_mv | 10.3390/cancers15030688 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_447839</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A743009899</galeid><sourcerecordid>A743009899</sourcerecordid><originalsourceid>FETCH-LOGICAL-c564t-c5b0fa25a8971d021f2cf8d6fd866d47f38da06659d83b1a9647eabe48915a663</originalsourceid><addsrcrecordid>eNp9kktvHCEMgEdVqyZKc-6tQuqlh07CYwaGS6XVJn1IaSL1dUUseDYkDKQw01X-fdnsNs1GVUECy_5sbOOqeknwEWMSHxsdDKRMWsww77on1T7Fgtacy-bpA3mvOsz5CpfFGBFcPK_2GBe85Q3fr1azaYxuGKYASAeLPsOoF9E7g05cBp0h36nHS0BfXL5GsUenOvnb-iJkGNE8-pjAjNqj-V02b5FG53p0MaycBXQOeQRbbBnqeQxjih59HSd7-6J61muf4XB7H1Tf359-m3-szy4-fJrPzmpT8hvLucC9pq3upCAWU9JT03eW97bj3DaiZ53VmPNW2o4tiJa8EaAX0HSStJpzdlDVm7h5BTfTQt0kN-h0q6J2aqu6LhKophEdk__lT9yPmYppqbybFJG0EbTw7zZ8gQewBkqN2u-47VqCu1TL-EtJSVj5gxLgzTZAij-n0i41uGzAex0gTllRIVpOW0nX6OtH6FWcUijtW1OlZNoQ-Zdaag_KhT6Wd806qJqJhmEsO7mmjv5BlW1hcCYG6F3R7zgcbxxMijkn6O9rJFitx1E9Gsfi8epha-75P8PHfgNTtNyV</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2774892419</pqid></control><display><type>article</type><title>Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>SWEPUB Freely available online</source><source>PubMed Central Open Access</source><creator>Lundqvist, Erik ; Myrberg, Ida Hed ; Boman, Sol Erika ; Saraste, Deborah ; Weibull, Caroline E ; Landerholm, Kalle ; Haapaniemi, Staffan ; Martling, Anna ; Myrelid, Pär ; Nordenvall, Caroline</creator><creatorcontrib>Lundqvist, Erik ; Myrberg, Ida Hed ; Boman, Sol Erika ; Saraste, Deborah ; Weibull, Caroline E ; Landerholm, Kalle ; Haapaniemi, Staffan ; Martling, Anna ; Myrelid, Pär ; Nordenvall, Caroline</creatorcontrib><description>Incidence of early-onset (<50 years) colorectal cancer (EOCRC) is increasing in developed countries. The aim was to investigate autoimmune and metabolic conditions as risk factors for EOCRC. In a nationwide nested case-control study, we included all EOCRC cases in Sweden diagnosed during 2007-2016, together with controls, matched for birth year, sex, and county. Information on exposure of autoimmune or metabolic disease was collected from the National Patient Register and Prescribed Drugs Registry. Hazard ratios (HR) as measures of the association between EOCRC and the exposures were estimated using conditional logistic regression. In total, 2626 EOCRC patients and 15,756 controls were included. A history of metabolic disease nearly doubled the incidence hazard of EOCRC (HR 1.82, 95% CI 1.66-1.99). A sixfold increased incidence hazard of EOCRC (HR 5.98, 95% CI 4.78-7.48) was seen in those with inflammatory bowel disease (IBD), but the risk increment decreased in presence of concomitant metabolic disease (HR 3.65, 95% CI 2.57-5.19). Non-IBD autoimmune disease was not statistically significantly associated with EOCRC. IBD and metabolic disease are risk factors for EOCRC and should be considered in screening guidelines.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers15030688</identifier><identifier>PMID: 36765646</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Age ; Autoimmune diseases ; Cancer ; Cholangitis ; Codes ; Colorectal cancer ; Colorectal carcinoma ; Comorbidity ; Complications and side effects ; Diabetes ; Disease ; Drugs ; Gastrointestinal diseases ; Hyperlipidemia ; Hypertension ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Intestine ; Medical screening ; Metabolic diseases ; Metabolic disorders ; Obesity ; Oncology, Experimental ; Patients ; Prescribing ; Risk factors ; Tumors ; Type 2 diabetes ; Womens health</subject><ispartof>CANCERS, 2023, Vol.15 (3), p.688</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c564t-c5b0fa25a8971d021f2cf8d6fd866d47f38da06659d83b1a9647eabe48915a663</citedby><cites>FETCH-LOGICAL-c564t-c5b0fa25a8971d021f2cf8d6fd866d47f38da06659d83b1a9647eabe48915a663</cites><orcidid>0000-0001-5312-1023 ; 0000-0002-5112-8894 ; 0000-0002-8297-2238 ; 0000-0001-7518-9213</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913656/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913656/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,550,723,776,780,881,4010,27902,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36765646$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-192472$$DView record from Swedish Publication Index$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:152026849$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Lundqvist, Erik</creatorcontrib><creatorcontrib>Myrberg, Ida Hed</creatorcontrib><creatorcontrib>Boman, Sol Erika</creatorcontrib><creatorcontrib>Saraste, Deborah</creatorcontrib><creatorcontrib>Weibull, Caroline E</creatorcontrib><creatorcontrib>Landerholm, Kalle</creatorcontrib><creatorcontrib>Haapaniemi, Staffan</creatorcontrib><creatorcontrib>Martling, Anna</creatorcontrib><creatorcontrib>Myrelid, Pär</creatorcontrib><creatorcontrib>Nordenvall, Caroline</creatorcontrib><title>Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study</title><title>CANCERS</title><addtitle>Cancers (Basel)</addtitle><description>Incidence of early-onset (<50 years) colorectal cancer (EOCRC) is increasing in developed countries. The aim was to investigate autoimmune and metabolic conditions as risk factors for EOCRC. In a nationwide nested case-control study, we included all EOCRC cases in Sweden diagnosed during 2007-2016, together with controls, matched for birth year, sex, and county. Information on exposure of autoimmune or metabolic disease was collected from the National Patient Register and Prescribed Drugs Registry. Hazard ratios (HR) as measures of the association between EOCRC and the exposures were estimated using conditional logistic regression. In total, 2626 EOCRC patients and 15,756 controls were included. A history of metabolic disease nearly doubled the incidence hazard of EOCRC (HR 1.82, 95% CI 1.66-1.99). A sixfold increased incidence hazard of EOCRC (HR 5.98, 95% CI 4.78-7.48) was seen in those with inflammatory bowel disease (IBD), but the risk increment decreased in presence of concomitant metabolic disease (HR 3.65, 95% CI 2.57-5.19). Non-IBD autoimmune disease was not statistically significantly associated with EOCRC. IBD and metabolic disease are risk factors for EOCRC and should be considered in screening guidelines.</description><subject>Age</subject><subject>Autoimmune diseases</subject><subject>Cancer</subject><subject>Cholangitis</subject><subject>Codes</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Comorbidity</subject><subject>Complications and side effects</subject><subject>Diabetes</subject><subject>Disease</subject><subject>Drugs</subject><subject>Gastrointestinal diseases</subject><subject>Hyperlipidemia</subject><subject>Hypertension</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Intestine</subject><subject>Medical screening</subject><subject>Metabolic diseases</subject><subject>Metabolic disorders</subject><subject>Obesity</subject><subject>Oncology, Experimental</subject><subject>Patients</subject><subject>Prescribing</subject><subject>Risk factors</subject><subject>Tumors</subject><subject>Type 2 diabetes</subject><subject>Womens health</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><sourceid>D8T</sourceid><recordid>eNp9kktvHCEMgEdVqyZKc-6tQuqlh07CYwaGS6XVJn1IaSL1dUUseDYkDKQw01X-fdnsNs1GVUECy_5sbOOqeknwEWMSHxsdDKRMWsww77on1T7Fgtacy-bpA3mvOsz5CpfFGBFcPK_2GBe85Q3fr1azaYxuGKYASAeLPsOoF9E7g05cBp0h36nHS0BfXL5GsUenOvnb-iJkGNE8-pjAjNqj-V02b5FG53p0MaycBXQOeQRbbBnqeQxjih59HSd7-6J61muf4XB7H1Tf359-m3-szy4-fJrPzmpT8hvLucC9pq3upCAWU9JT03eW97bj3DaiZ53VmPNW2o4tiJa8EaAX0HSStJpzdlDVm7h5BTfTQt0kN-h0q6J2aqu6LhKophEdk__lT9yPmYppqbybFJG0EbTw7zZ8gQewBkqN2u-47VqCu1TL-EtJSVj5gxLgzTZAij-n0i41uGzAex0gTllRIVpOW0nX6OtH6FWcUijtW1OlZNoQ-Zdaag_KhT6Wd806qJqJhmEsO7mmjv5BlW1hcCYG6F3R7zgcbxxMijkn6O9rJFitx1E9Gsfi8epha-75P8PHfgNTtNyV</recordid><startdate>2023</startdate><enddate>2023</enddate><creator>Lundqvist, Erik</creator><creator>Myrberg, Ida Hed</creator><creator>Boman, Sol Erika</creator><creator>Saraste, Deborah</creator><creator>Weibull, Caroline E</creator><creator>Landerholm, Kalle</creator><creator>Haapaniemi, Staffan</creator><creator>Martling, Anna</creator><creator>Myrelid, Pär</creator><creator>Nordenvall, Caroline</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>ABXSW</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>DG8</scope><scope>ZZAVC</scope><orcidid>https://orcid.org/0000-0001-5312-1023</orcidid><orcidid>https://orcid.org/0000-0002-5112-8894</orcidid><orcidid>https://orcid.org/0000-0002-8297-2238</orcidid><orcidid>https://orcid.org/0000-0001-7518-9213</orcidid></search><sort><creationdate>2023</creationdate><title>Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study</title><author>Lundqvist, Erik ; Myrberg, Ida Hed ; Boman, Sol Erika ; Saraste, Deborah ; Weibull, Caroline E ; Landerholm, Kalle ; Haapaniemi, Staffan ; Martling, Anna ; Myrelid, Pär ; Nordenvall, Caroline</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c564t-c5b0fa25a8971d021f2cf8d6fd866d47f38da06659d83b1a9647eabe48915a663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Age</topic><topic>Autoimmune diseases</topic><topic>Cancer</topic><topic>Cholangitis</topic><topic>Codes</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Comorbidity</topic><topic>Complications and side effects</topic><topic>Diabetes</topic><topic>Disease</topic><topic>Drugs</topic><topic>Gastrointestinal diseases</topic><topic>Hyperlipidemia</topic><topic>Hypertension</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Intestine</topic><topic>Medical screening</topic><topic>Metabolic diseases</topic><topic>Metabolic disorders</topic><topic>Obesity</topic><topic>Oncology, Experimental</topic><topic>Patients</topic><topic>Prescribing</topic><topic>Risk factors</topic><topic>Tumors</topic><topic>Type 2 diabetes</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lundqvist, Erik</creatorcontrib><creatorcontrib>Myrberg, Ida Hed</creatorcontrib><creatorcontrib>Boman, Sol Erika</creatorcontrib><creatorcontrib>Saraste, Deborah</creatorcontrib><creatorcontrib>Weibull, Caroline E</creatorcontrib><creatorcontrib>Landerholm, Kalle</creatorcontrib><creatorcontrib>Haapaniemi, Staffan</creatorcontrib><creatorcontrib>Martling, Anna</creatorcontrib><creatorcontrib>Myrelid, Pär</creatorcontrib><creatorcontrib>Nordenvall, Caroline</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>SWEPUB Linköpings universitet full text</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SWEPUB Linköpings universitet</collection><collection>SwePub Articles full text</collection><jtitle>CANCERS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lundqvist, Erik</au><au>Myrberg, Ida Hed</au><au>Boman, Sol Erika</au><au>Saraste, Deborah</au><au>Weibull, Caroline E</au><au>Landerholm, Kalle</au><au>Haapaniemi, Staffan</au><au>Martling, Anna</au><au>Myrelid, Pär</au><au>Nordenvall, Caroline</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study</atitle><jtitle>CANCERS</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023</date><risdate>2023</risdate><volume>15</volume><issue>3</issue><spage>688</spage><pages>688-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Incidence of early-onset (<50 years) colorectal cancer (EOCRC) is increasing in developed countries. The aim was to investigate autoimmune and metabolic conditions as risk factors for EOCRC. In a nationwide nested case-control study, we included all EOCRC cases in Sweden diagnosed during 2007-2016, together with controls, matched for birth year, sex, and county. Information on exposure of autoimmune or metabolic disease was collected from the National Patient Register and Prescribed Drugs Registry. Hazard ratios (HR) as measures of the association between EOCRC and the exposures were estimated using conditional logistic regression. In total, 2626 EOCRC patients and 15,756 controls were included. A history of metabolic disease nearly doubled the incidence hazard of EOCRC (HR 1.82, 95% CI 1.66-1.99). A sixfold increased incidence hazard of EOCRC (HR 5.98, 95% CI 4.78-7.48) was seen in those with inflammatory bowel disease (IBD), but the risk increment decreased in presence of concomitant metabolic disease (HR 3.65, 95% CI 2.57-5.19). Non-IBD autoimmune disease was not statistically significantly associated with EOCRC. IBD and metabolic disease are risk factors for EOCRC and should be considered in screening guidelines.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36765646</pmid><doi>10.3390/cancers15030688</doi><orcidid>https://orcid.org/0000-0001-5312-1023</orcidid><orcidid>https://orcid.org/0000-0002-5112-8894</orcidid><orcidid>https://orcid.org/0000-0002-8297-2238</orcidid><orcidid>https://orcid.org/0000-0001-7518-9213</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | CANCERS, 2023, Vol.15 (3), p.688 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_447839 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; SWEPUB Freely available online; PubMed Central Open Access |
| subjects | Age Autoimmune diseases Cancer Cholangitis Codes Colorectal cancer Colorectal carcinoma Comorbidity Complications and side effects Diabetes Disease Drugs Gastrointestinal diseases Hyperlipidemia Hypertension Inflammatory bowel disease Inflammatory bowel diseases Intestine Medical screening Metabolic diseases Metabolic disorders Obesity Oncology, Experimental Patients Prescribing Risk factors Tumors Type 2 diabetes Womens health |
| title | Autoimmune and Metabolic Diseases and the Risk of Early-Onset Colorectal Cancer, a Nationwide Nested Case-Control Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T19%3A20%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Autoimmune%20and%20Metabolic%20Diseases%20and%20the%20Risk%20of%20Early-Onset%20Colorectal%20Cancer,%20a%20Nationwide%20Nested%20Case-Control%20Study&rft.jtitle=CANCERS&rft.au=Lundqvist,%20Erik&rft.date=2023&rft.volume=15&rft.issue=3&rft.spage=688&rft.pages=688-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers15030688&rft_dat=%3Cgale_swepu%3EA743009899%3C/gale_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2774892419&rft_id=info:pmid/36765646&rft_galeid=A743009899&rfr_iscdi=true |